Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.

摘要

Bitetto et al. described how vitamin D serum level is complementary to the interleukin 28B (IL28B; rsl297986O) polymorphism in predicting the achievement of sustained virological response (SVR) in treatment-naive patients receiving standard pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C virus (HCV).It should be also noted how vitamin D serum levels may be influenced by polymorphisms in the gene coding for a related metabolic enzyme (cytochrome P450 27B1 [CYP27B1]).2 The association between responsiveness to therapy for difficult-to-treat HCV infections and IL28B (rsl2979860 and rs8099917) single-nucleotide polymorphisms (SNPs) were evaluated.